Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Research & Development (2016 - 2025)

Historic Research & Development for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $2.7 million.

  • Catalyst Pharmaceuticals' Research & Development fell 1909.26% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year increase of 3583.44%. This contributed to the annual value of $12.6 million for FY2024, which is 8642.19% down from last year.
  • Catalyst Pharmaceuticals' Research & Development amounted to $2.7 million in Q3 2025, which was down 1909.26% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Research & Development registered a high of $83.7 million during Q3 2023, and its lowest value of $2.0 million during Q4 2023.
  • Moreover, its 5-year median value for Research & Development was $3.9 million (2025), whereas its average is $8.1 million.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Research & Development skyrocketed by 90676.29% in 2023, and later plummeted by 9607.47% in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Research & Development stood at $5.0 million in 2021, then decreased by 18.01% to $4.1 million in 2022, then tumbled by 51.82% to $2.0 million in 2023, then soared by 92.6% to $3.8 million in 2024, then plummeted by 30.04% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $4.4 million for Q2 2025, and $3.9 million during Q1 2025.